Wockhardt Ltd continues its upward trend, increasing by 3.6% today, marking a five-day winning streak for the company.

Wockhardt's antibiotic Zaynich, demonstrating promising efficacy and safety in trials, secures a favorable recommendation from the CDSCO expert committee, bringing it closer to achieving final approval.